Literature DB >> 11014622

Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital.

R Luzzati1, G Amalfitano, L Lazzarini, F Soldani, S Bellino, M Solbiati, M C Danzi, S Vento, G Todeschini, C Vivenza, E Concia.   

Abstract

In a retrospective study conducted in an Italian tertiary care hospital, the incidence of nosocomial candidemia was evaluated together with causative pathogens, treatment, and risk factors for death. Over a 6-year period (1992-1997), a total of 189 episodes of candidemia occurred in 189 patients (mean age 58+/-19 years), accounting for an average incidence of 1.14 episodes per 10,000 patient-days per year. The most common reasons for hospitalization were solid neoplasia (21%), trauma (17%), abdominal diseases requiring surgery (13%), and cardiovascular diseases (13%). No patient was neutropenic within 3 weeks prior to the onset of candidemia. One hundred thirty patients were hospitalized in intensive care units, 47 patients in surgical wards, and 12 patients in medical wards. Candida albicans was the most frequently isolated pathogen, accounting for 54% of fungal isolates, followed by Candida parapsilosis (23%), Candida glabrata (7%), Candida tropicalis (5%), Candida pelliculosa (4%), Candida lusitaniae (1%), Candida humicula (1%), and other non-albicans Candida spp. (5%). Seventy-six (41%) patients received adequate antifungal therapy. Seventy-one (58%) of the 123 evaluable patients with central venous catheters underwent line removal; 51 of them had catheter-related candidemia. The 30-day crude mortality rate was 45%. Older age, hospitalization in an intensive care unit, a longer duration of candidemia, retention of central lines, and inadequate antifungal therapy were significantly associated with poor outcome. In the present study, nosocomial candidemia was a frequent and relatively underestimated illness. Adequate antifungal therapy and central line removal independently reduced the high mortality of the disease.

Entities:  

Mesh:

Year:  2000        PMID: 11014622     DOI: 10.1007/s100960000325

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  39 in total

1.  Efficacy of micafungin for the treatment of candidemia.

Authors:  D Andes; N Safdar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-10       Impact factor: 3.267

2.  Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.

Authors:  Vânia Lúcia Ribeiro da Matta; Márcia de Souza Carvalho Melhem; Arnaldo Lopes Colombo; Maria Luiza Moretti; Laura Rodero; Gisele Madeira Duboc de Almeida; Marilena dos Anjos Martins; Silvia Figueiredo Costa; Maria Beatriz G Souza Dias; Márcio Nucci; Anna S Levin
Journal:  Antimicrob Agents Chemother       Date:  2007-01-29       Impact factor: 5.191

Review 3.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

Review 4.  Candida identification: a journey from conventional to molecular methods in medical mycology.

Authors:  Mohammad Zubair Alam; Qamre Alam; Asif Jiman-Fatani; Mohammad Amjad Kamal; Adel M Abuzenadah; Adeel G Chaudhary; Mohammad Akram; Absarul Haque
Journal:  World J Microbiol Biotechnol       Date:  2014-01-01       Impact factor: 3.312

Review 5.  Epidemiology, incidence and risk factors for invasive candidiasis in high-risk patients.

Authors:  Ercole Concia; Anna Maria Azzini; Michela Conti
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 6.  [Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine].

Authors:  C Lichtenstern; S Swoboda; M Hirschburger; E Domann; T Hoppe-Tichy; M Winkler; C Lass-Flörl; M A Weigand
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

7.  Development and characterization of an in vivo central venous catheter Candida albicans biofilm model.

Authors:  D Andes; J Nett; P Oschel; R Albrecht; K Marchillo; A Pitula
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

8.  Modified colorimetric assay for susceptibility testing of azole antifungal drugs against Candida species.

Authors:  Jian Chen; Zhe Wan; Ruoyu Li
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

9.  Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

10.  Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B.

Authors:  Bertrand F Dupont; Olivier Lortholary; Luis Ostrosky-Zeichner; Flavie Stucker; Vijay Yeldandi
Journal:  Crit Care       Date:  2009-10-05       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.